The presence or absence of these receptors are used to create the clinical subtypes of Triple Negative Breast Cancer (ER, PR, and HER2 negative), HER2+ breast cancer, and Luminal A breast cancer (ER and PR positive, HER2 negative). Here, ERBB2 is linked to breast cancer.